Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGc-043 in EBV-Related Diseases
NCT07349836Phase 1Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Vaccine mRNA, mRNA Vaccines, Cancer Vaccines
01
Overview
Phase 1 trial of WGc-043 in Epstein-Barr Virus-Associated Neoplasm (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Adverse Events at 2 years. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
WGc-043
03
Conditions
Epstein-Barr Virus-Associated Neoplasm
Beyond the preview
Go deeper on NCT07349836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349836.